Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001601830-25-000127
Filing Date
2025-08-05
Accepted
2025-08-05 06:33:05
Documents
85
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rxrx-20250630.htm   iXBRL 10-Q 1149925
2 EX-31.1 exhibit311-q0225.htm EX-31.1 7595
3 EX-31.2 exhibit312-q0225.htm EX-31.2 7567
4 EX-32.1 exhibit321-q0225.htm EX-32.1 3987
10 rxrx-20250630_g1.jpg GRAPHIC 389713
11 rxrx-20250630_g2.jpg GRAPHIC 512609
  Complete submission text file 0001601830-25-000127.txt   9440052

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rxrx-20250630.xsd EX-101.SCH 58189
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rxrx-20250630_cal.xml EX-101.CAL 83502
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rxrx-20250630_def.xml EX-101.DEF 278281
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rxrx-20250630_lab.xml EX-101.LAB 715330
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rxrx-20250630_pre.xml EX-101.PRE 485353
88 EXTRACTED XBRL INSTANCE DOCUMENT rxrx-20250630_htm.xml XML 866722
Mailing Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101
Business Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101 (385) 269-0203
RECURSION PHARMACEUTICALS, INC. (Filer) CIK: 0001601830 (see all company filings)

EIN.: 464099738 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)